Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
12,182,092
-
Shares change
-
+357,251
-
Total reported value, excl. options
-
$562,840,664
-
Value change
-
+$17,606,359
-
Put/Call ratio
-
41.46%
-
Number of buys
-
64
-
Number of sells
-
-41
-
Price
-
$46.2
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2020
136 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12,182,092 shares
.
Largest 10 shareholders include FMR LLC (2,001,988 shares), STATE STREET CORP (1,673,996 shares), Artemis Investment Management LLP (1,013,448 shares), VANGUARD GROUP INC (908,784 shares), BlackRock Inc. (899,806 shares), CITADEL ADVISORS LLC (814,242 shares), ALLIANCEBERNSTEIN L.P. (685,411 shares), VICTORY CAPITAL MANAGEMENT INC (684,989 shares), Avidity Partners Management LP (547,000 shares), and Logos Global Management LP (430,000 shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.